A detailed history of Royal Bank Of Canada transactions in Bio Atla, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 28 shares of BCAB stock, worth $48. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28
Previous 3,016 99.07%
Holding current value
$48
Previous $4,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.17 - $2.05 $3,495 - $6,125
-2,988 Reduced 99.07%
28 $0
Q2 2024

Aug 14, 2024

BUY
$1.37 - $3.92 $2,204 - $6,307
1,609 Added 114.36%
3,016 $4,000
Q1 2024

Nov 05, 2024

SELL
$1.88 - $3.46 $3,024 - $5,567
-1,609 Reduced 53.35%
1,407 $4,000
Q1 2024

May 15, 2024

SELL
$1.88 - $3.46 $21,977 - $40,447
-11,690 Reduced 89.26%
1,407 $4,000
Q4 2023

Feb 14, 2024

BUY
$1.27 - $3.18 $407 - $1,020
321 Added 2.51%
13,097 $32,000
Q3 2023

Nov 14, 2023

BUY
$1.7 - $3.07 $13,853 - $25,017
8,149 Added 176.12%
12,776 $21,000
Q2 2023

Aug 14, 2023

BUY
$2.83 - $3.87 $13,063 - $17,863
4,616 Added 41963.64%
4,627 $13,000
Q1 2023

May 15, 2023

SELL
$2.3 - $8.25 $117 - $420
-51 Reduced 82.26%
11 $0
Q4 2022

Feb 14, 2023

SELL
$6.29 - $11.01 $25 - $44
-4 Reduced 6.06%
62 $0
Q3 2022

Nov 14, 2022

BUY
$2.94 - $11.87 $182 - $735
62 Added 1550.0%
66 $0
Q2 2022

Aug 15, 2022

SELL
$2.13 - $5.38 $2,032 - $5,132
-954 Reduced 99.58%
4 $0
Q1 2022

May 16, 2022

SELL
$4.38 - $18.78 $10,078 - $43,212
-2,301 Reduced 70.6%
958 $5,000
Q4 2021

Feb 14, 2022

BUY
$19.0 - $30.95 $37,202 - $60,600
1,958 Added 150.5%
3,259 $63,000
Q3 2021

Nov 15, 2021

BUY
$29.44 - $43.74 $13,719 - $20,382
466 Added 55.81%
1,301 $38,000
Q2 2021

Aug 16, 2021

BUY
$38.07 - $56.17 $31,788 - $46,901
835 New
835 $35,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $62.4M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.